Compare Ginkgo Bioworks Holdings Inc (DNA) vs TKO Group Holdings Inc (TKO) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

TKO trades at $194.10, up 2.47% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 results showed revenue growth of 18% year-over-year to $1.55 billion, though EPS of $1.34 missed estimates. The company raised full-year guidance, reflecting confidence in media rights and live events. Valuation metrics like a P/E of 68.33 appear elevated relative to earnings.

The outlook is positive given raised guidance and dominant market position in sports entertainment, but high valuation and recent earnings misses pose risks. Upside to the consensus price target of $228.17 suggests potential growth, dependent on execution of growth initiatives and macroeconomic stability.